7707 Fannin Street
Houston, TX 77054
Full-time employees: 31
|Mr. Pietro Bersani CPA, J.D.||CEO, Principal Financial Officer & Director||546.76k||N/A||1968|
|Jason Morris||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Leonardo Mirandola Ph.D.||CSO & Interim COO||N/A||N/A||N/A|
|Dr. Scott Dahlbeck M.D., Pharm.D., PharmD||Chief of Staff||N/A||N/A||1962|
|Mr. Timothy Simkiss CPA||Controller||N/A||N/A||N/A|
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.